| Habib Dable is president of U.S. pharmaceuticals for Bayer, a role he has held since October 2015.
Previously, Habib was global head of specialty medicine for Bayer overseeing four therapeutic areas – hematology, oncology, ophthalmology, and neurology. Habib started at Bayer in 1994 as a sales representative and has held several sales, marketing, and strategic planning roles in Canada, Japan and the U.S. He was appointed vice president and regional business unit head for Latin America, Canada, Asia Pacific, and Japan and then head of Bayer’s global ophthalmology team, leading the launch of EYLEA® (aflibercept), the company’s treatment for macular degeneration. Habib earned his MBA from the University of New Brunswick in Canada, where he also completed his undergraduate study. |
